The genesis of Zelboraf: Targeting mutant B-Raf in melanoma

The protein kinase B-Raf is a critical component of the Ras/MAPK signaling pathway. An oncogenic B-Raf mutation that constitutively activates the kinase was identified in z50% of melanoma patients and in other cancers. A structure-guided drug discovery approach enabled the development of Zelboraf, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Matthew J., Schlessinger, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2012
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461519/
https://www.ncbi.nlm.nih.gov/pubmed/23027900
http://dx.doi.org/10.1083/jcb.201205167
_version_ 1782245093673009152
author Davis, Matthew J.
Schlessinger, Joseph
author_facet Davis, Matthew J.
Schlessinger, Joseph
author_sort Davis, Matthew J.
collection PubMed
description The protein kinase B-Raf is a critical component of the Ras/MAPK signaling pathway. An oncogenic B-Raf mutation that constitutively activates the kinase was identified in z50% of melanoma patients and in other cancers. A structure-guided drug discovery approach enabled the development of Zelboraf, a targeted inhibitor of oncogenic B-Raf. This drug has been used successfully in the clinic to treat metastatic melanoma patients harboring B-Raf mutations.
format Online
Article
Text
id pubmed-3461519
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-34615192013-04-01 The genesis of Zelboraf: Targeting mutant B-Raf in melanoma Davis, Matthew J. Schlessinger, Joseph J Cell Biol News The protein kinase B-Raf is a critical component of the Ras/MAPK signaling pathway. An oncogenic B-Raf mutation that constitutively activates the kinase was identified in z50% of melanoma patients and in other cancers. A structure-guided drug discovery approach enabled the development of Zelboraf, a targeted inhibitor of oncogenic B-Raf. This drug has been used successfully in the clinic to treat metastatic melanoma patients harboring B-Raf mutations. The Rockefeller University Press 2012-10-01 /pmc/articles/PMC3461519/ /pubmed/23027900 http://dx.doi.org/10.1083/jcb.201205167 Text en © 2012 Davis and Schlessinger This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle News
Davis, Matthew J.
Schlessinger, Joseph
The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
title The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
title_full The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
title_fullStr The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
title_full_unstemmed The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
title_short The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
title_sort genesis of zelboraf: targeting mutant b-raf in melanoma
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461519/
https://www.ncbi.nlm.nih.gov/pubmed/23027900
http://dx.doi.org/10.1083/jcb.201205167
work_keys_str_mv AT davismatthewj thegenesisofzelboraftargetingmutantbrafinmelanoma
AT schlessingerjoseph thegenesisofzelboraftargetingmutantbrafinmelanoma
AT davismatthewj genesisofzelboraftargetingmutantbrafinmelanoma
AT schlessingerjoseph genesisofzelboraftargetingmutantbrafinmelanoma

Ejemplares similares